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Abstract
The HIV vaccine strategy that, to date, generated immune protection consisted of a prime-boost regimen using a canarypox
vector and an HIV envelope protein with alum, as shown in the RV144 trial. Since the efficacy was weak, and previous HIV
vaccine trials designed to generate antibody responses failed, we hypothesized that generation of T cell responses would
result in improved protection. Thus, we tested the immunogenicity of a similar envelope-based vaccine using a mouse
model, with two modifications: a clade C CN54gp140 HIV envelope protein was adjuvanted by the TLR9 agonist IC31H, and
the viral vector was the vaccinia strain NYVAC-CN54 expressing HIV envelope gp120. The use of IC31H facilitated
immunoglobulin isotype switching, leading to the production of Env-specific IgG2a, as compared to protein with alum
alone. Boosting with NYVAC-CN54 resulted in the generation of more robust Th1 T cell responses. Moreover, gp140 prime
with IC31H and alum followed by NYVAC-CN54 boost resulted in the formation and persistence of central and effector
memory populations in the spleen and an effector memory population in the gut. Our data suggest that this regimen is
promising and could improve the protection rate by eliciting strong and long-lasting humoral and cellular immune
responses.
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Introduction
Human immunodeficiency virus (HIV) is responsible for nearly
two million deaths annually, and although the overall incidence
appears to have stabilized, the epidemic continues to spread
(WHO, 2011). A vaccine represents the best possibility for
eradication of the virus, but despite unprecedented efforts, an
effective vaccine has not yet been developed.
Two recent vaccine efficacy trials provide clues to potential
components that can contribute to protective immunity against
HIV. Specifically, the Step study used a mixture of recombinant
adenovirus serotype 5 (Ad5) vectors expressing HIV-1 proteins
[1,2]. That study terminated early after interim analyses demon-
strated that the vaccine neither prevented infection nor lowered
viral load, and perhaps had the adverse effect of increasing HIV
acquisition in subjects with preexisting Ad5 neutralizing antibod-
ies. Though the reasons for this remain unclear, follow up
investigations indicated that adenovirus-specific CD4+ T cells
might have impacted the availability of potential HIV target cells
[3,4]. In contrast, the RV144 trial was the first ever to demonstrate
modest protection from HIV infection [5]. That trial used an
ALVAC-HIV prime in combination with a VaxGen AIDSVAX
bivalent gp120 clade B/E protein boost. The regimen induced
mostly humoral and low-level CD4+ T-cell responses, supporting
the hypothesis that balancing both arms of the immune response
will induce improved protection.
New York vaccinia virus (NYVAC) vector is a highly attenuated
Copenhagen virus strain capable of inducing humoral and T-cell
responses [6,7]. NYVAC-CN54 encodes cell-released HIV-1 Env
gp120 and Gag/Pol/Nef, an intracellular polyprotein harboring
cytotoxic T lymphocyte epitopes [8]. Preclinical studies in mice
demonstrated that this vector, when used as a boost after a DNA
prime, induces HIV-specific CD8+ T-cell responses and IgG
production [8,9]. In monkeys, a similar NYVAC vector expressing
HIV gp120 and SIV Gag/Pol/Nef induced CD4+ and CD8+ T
cells and antibodies to Env, with protection following SHIV89.6p
challenge [10]. In a phase I clinical trial NYVAC-CN54 induced a
robust immune response, in particular Env-specific IFN-c
production by CD4+ and CD8+ T cells [11]. Additionally,
vaccinia viruses are advantageous vaccine vectors because pre-
existing immunity at the population level is restricted to aged
groups, since smallpox vaccination was terminated in the mid-
1970s. Even in individuals with pre-existing immunity, smallpox-
specific T cells are less frequent in the mucosal tissues of healthy
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volunteers than adenovirus-specific T cells [12], suggesting that
use of this vector may avoid problems encountered in the Step
study. Finally, vaccinia viruses are capable of activating innate
immune responses through TLR-dependent pathways [13,14].
TLR activation is recognized as a key component in several
vaccines, including the yellow fever vaccine, the activity of which
seems largely to be due to the generation of Th1-inducing mature
DCs [15]. Such findings have opened a new field of research on
novel adjuvants, many of which are TLR ligands, to mimic the
pathogen-associated molecular patterns recognized during an
encounter with a natural pathogen.
Thus far, eleven TLRs have been identified in mice. Among
them, TLR3, TLR7, TLR8 and TLR9 recognize nucleic acids; in
particular, TLR9 recognizes CpG motif-containing DNA se-
quences. Several CpG oligodeoxynucleotide (CpG ODN) formu-
lations have already been used as adjuvants in vaccine studies for
infectious diseases, including HIV [16,17]. In this regard, CpG
ODN was shown to improve the humoral and cellular responses in
a vaccination regimen consisting of Gag protein prime and
adenovirus boost, both in mice [18] and in a primate model [19].
The recently developed compound IC31 consists of a combination
of ODN1a, a TLR9 ligand, and the antimicrobial peptide
KLKL5KLK, which contributes to the stabilization of ODN1a
and to depot formation [20]. This combination was shown to
induce a strong cellular and humoral immune response through
activation of DCs and antigen-specific T-cell proliferation.
Furthermore, IC31 increases the activation and cytotoxic activity
of CD8+ T cells [21].
In this study we compared different vaccination regimens using
NYVAC-CN54 and recombinant Env-CN54 protein, in combi-
nation with alum alone, with IC31 alone, or with IC31 and alum
together. We evaluated induction of Env-specific antibodies,
CD4+ and CD8+ T-cell effector function, and the formation of
mucosal central and effector memory T-cell subsets. Our findings
indicate that IC31 greatly improves vaccination immunogenicity
in terms of the development of the Env-specific response.
Materials and Methods
Mice
Female BALB/c mice, 5 to 6 weeks old, were purchased from
Harlan Laboratory (Indianapolis, IN) and maintained in the Fred
Hutchinson Cancer Research Center (FHCRC) animal health
resource facility under pathogen-free conditions.
Ethics statement
All experiments were approved by the FHCRC institutional
animal care and use committee. The Office of Laboratory Animal
Welfare has approved the FHCRC’s Animal Welfare Assurance
(#A3226-01).
Reagents
Purified recombinant HIV-1 Env-CN54 gp140 was manufac-
tured by Polymun (Vienna, Austria). IC31H is a proprietary
formulation developed by Intercell (Vienna, Austria) and was
supplied by the manufacturer. Alhydrogel (alum) was from
Brenntag (Frederikssund, Denmark). The development and
immunogenicity of NYVAC-CN54 were previously described
[8]. Env peptides spanning the complete CN54gp140 protein
sequence were synthesized as 15-mers overlapping by 11 amino
acids by Biosynthesis (Lewisville, TX), and were pooled sequen-
tially at 40 peptides per pool (Table 1).
Vaccine regimens and injections
Mice were divided into 10 test cohorts of 15 mice each, except
for the two groups that received protein adjuvanted with alum
only, where nine mice each were used. Five cohorts received
NYVAC-CN54 as prime and CN54 protein as boost, while the
other five cohorts received CN54 protein as prime and NYVAC-
CN54 as boost. As a placebo control, two additional cohorts of
nine mice each received saline alone. For all test cohorts NYVAC-
CN54 was administered at 107 PFU per injection; Env-CN54 was
given at 10 mg/mouse per injection. For Env-CN54 adjuvanted
with alum alone or with alum and IC31 together, protein was
mixed with alum (20 mg) for 1 hour at room temperature with
gentle agitation in a Tris buffered solution (20 mM Tris, 150 mM
NaCl, pH 7.5). Where indicated, IC31, at a concentration of
1.4 nmol ODN1a (‘‘IC31 medium’’) or 4 nmol ODN1a (‘‘IC31
high’’), was then added to the protein with alum. For protein
adjuvanted with IC31 alone, the same concentrations were used.
Mice were intramuscularly injected in the rear quadriceps using a
28-gauge insulin syringe. A schematic representation of the
injection schedules and regimens is shown in Figure 1.
Detection of HIV-1 Env-specific antibodies
Serum was obtained from mice at weeks 5, 11 and 15 and
ELISAs were performed following standard procedures. 2HB
plates (96-well; Nalge Nunc, Rochester, NY) were coated
overnight with 0.9 mg/ml HIV Env-CN54 protein, then washed
with buffer (150 mM NaCl, 0.1% Tween 20 in water), blocked for
1 h in 5% nonfat milk with 3% heat-inactivated goat serum and
0.2% Tween 20 in PBS, and then washed again. The serum
samples were serially diluted in blocking buffer, then added to the
wells in duplicate and incubated for 2 h at 37uC. The plates were
then washed, and HRP-conjugated anti-mouse IgG (Thermo
Scientific, Waltham, MA), anti-mouse IgG1-HRP, or anti-mouse
IgG2a-HRP (both from SouthernBiotech, Birmingham, AL) was
added at 1:2500 dilution and incubated for 1 h at 37uC. After
washing, the plates were developed with soluble 3,39-5,59-
tetramethylbenzene (BM blue POD substrate; Roche Applied
Science, Indianapolis, IN); the reaction was stopped by addition of
1 M H2SO4 and the optical density (OD) was read at 450 nm
using a SpectraMax M2 plate reader (Molecular Devices,
Sunnyvale, CA). The reported titers correspond to the reciprocal
of the highest serum dilution showing a four-times higher OD
value than background.
Intracellular cytokine staining and measurement of
cellular proliferation by CFSE dilution
Fresh cells from individual spleens or MLN were stimulated for
5 h with one pool of Env-CN54 peptides, with 0.08% DMSO
(peptide diluent) alone as a negative control, or with 1 mg/ml of
Table 1. Aminoacid residues included in each of the four
peptide pools used for in vitro stimulations, and their location
in the Env protein structure.
Pool AA position Env structure
1 31–201 V1–V2
2 191–361 V3
3 351–517 V4–V5
4 507–665 gp41
doi:10.1371/journal.pone.0042163.t001
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anti-CD3 and 0.5 mg/ml anti-CD28 as a positive control, adding
10 mg/ml Brefeldin A (eBioscience, San Diego, CA) during the
incubation. The cells were then washed, blocked for 10 min with
0.5 mg/ml anti-CD16/CD32 in PBS containing 2% FBS and then
the surface staining was performed. The cells were then washed
and fixed with fixation permeabilization buffer (eBioscience) for
30 minutes at 4uC. The intracellular staining was then performed
and the samples were analyzed on a BD LSRII system (BD
Biosciences, Franklin Lakes, NJ). FACS data were analyzed using
FlowJo software (TreeStar, Ashland, OR). All antibodies used for
stimulation, sorting and staining were obtained from eBioscience,
and included anti-CD4 (clone GK1.5), anti-CD8 (clone 53-6.7),
anti-CD127 (clone A7R34), anti-KLRG1 (clone 2F1), anti-CD62L
(clone MEL-14), anti-IFN-c (clone XMG1.2), anti-TNF-a (clone
MP6-XT22), anti-CD3 (clone 145-2C11), anti-CD28 (clone 37.51)
and anti-CD16/CD32 (clone 93).
To perform the cellular proliferation assay, 16106 splenocytes
from each mouse were resuspended in PBS containing 0.1% BSA.
Carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Grand
Island, NY) was added to reach a final concentration of 1 mM, and
the cells were incubated at room temperature for 5 minutes.
Culture medium containing 10% FBS was then added and the
cells were incubated for 5 minutes on ice, washed twice and then
plated at a concentration of 105 cells/well in the presence of Env-
CN54 peptide pool 1, DMSO alone, or anti-CD3/CD28 at the
same concentrations as used for the intracellular cytokine staining
stimulation. After three days of culture, cells were stained following
the intracellular cytokine staining protocol. Proliferation was
measured as the percentage of CFSE-low cells.
Statistical analyses
Data were analyzed by two-tailed unpaired Student’s t tests
using PRISM 5 software (GraphPad Software, La Jolla, CA).
Welch’s correction was applied for non-equally distributed
variances.
Results
All vaccinations elicited a humoral response to Env
We first examined the Env-specific antibody response following
administration of various vaccine regimens (Fig. 1). After priming
with protein, the groups receiving Env-IC31 induced at least a
three log increase in their IgG2a titer at week 5 as compared to
Env-alum alone (Fig. 2A). This difference was statistically
significant when the high dose of IC31 plus alum was used,
where a seven log-difference was achieved (p,0.05). We observed
a similar trend for total IgG and IgG1. After boosting with
NYVAC-CN54, serum IgG2a titers at week 11 trended slightly
higher in the groups that were primed with protein adjuvanted
with IC31 plus alum as compared to protein with either adjuvant
alone, although the differences were not significant. At week 15 we
did not observe any significant differences between the groups
(Fig. 2A).
Among mice primed with NYVAC-CN54 and boosted with
protein plus adjuvant, there were no differences in antibody
induction at weeks 11 or 15, regardless of adjuvant (Fig. 2B).
Figure 1. Schematic representation of the vaccination protocol. Three to five mice for each timepoint were injected at weeks 0 and 3 with
the prime and at weeks 6 and 9 with the boost. Mice were either injected with saline (negative control, three mice per group), with protein plus alum
alone, with protein plus a medium or high dose of IC31 alone, with protein plus alum and a medium or high dose of IC31, or with NYVAC-CN54 (five
mice per each group per timepoint). At week 5, 11 or 15, a subset of mice were sacrificed and antibody and T-cell responses were analyzed ex vivo.
doi:10.1371/journal.pone.0042163.g001
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Env-specific CD4+ T-cell responses are increased in
magnitude and durability by IC31-protein prime/NYVAC-
CN54 boost
Next we examined CD4+ T-cell responses two weeks after
protein prime (week 5) and two and six weeks after boosting with
NYVAC-CN54 (Fig. 1). We used decreased expression of CD62L
to indicate general T-cell activation, and observed a significant
increase in CD4+ T-cell activation at week 5 when the medium
dose of IC31 alone or the high dose of IC31 plus alum was used in
combination with protein versus the saline control (p,0.05 each;
Fig. 3A). Although the differences were not significant in all
groups, there was also a general trend for increased CD4+ T-cell
activation following the NYVAC-CN54 boost versus the saline
control at weeks 11 and 15 (Fig. 3A).
We also evaluated CD4+ T-cell function by measuring cytokine
secretion upon in vitro stimulation. Priming with Env-CN54
adjuvanted with IC31 at any dose, with or without alum, induced
a higher percentage of cytokine producing cells at week 5 as
compared to the saline control or to priming with Env-CN54
adjuvanted with alum alone (Fig. 3B). The median frequency of
cytokine-producing CD4+ T cells detected after stimulation with
peptide pool 1, which induced the majority of detectable
responses, ranged from 0.023% when the adjuvant was the
medium dose of IC31 alone, to 0.072% with the high dose of IC31
plus alum. Boosting with NYVAC-CN54 induced a two- to three-
fold increase in the CD4+ T-cell response in all regimens.
Moreover, mice immunized with the high dose of IC31 plus alum
had a significantly higher frequency of cytokine-producing CD4+
T cells versus those receiving the medium dose plus alum or alum
alone (0.204% for IC31 high/alum vs. 0.062% for IC31 medium/
alum and 0.018% for alum alone, p = 0.016 and p = 0.033,
respectively; Fig. 3B). Six weeks after the final immunization (week
15), we again observed that inclusion of IC31 with the protein
prime induced a CD4+ T-cell response of greater magnitude than
inclusion of alum alone (Fig. 3B). The CD4+ T-cell response to
peptide pool 1 is shown longitudinally in Fig. 3C, demonstrating
that adjuvanting the protein prime with the high dose of IC31,
alone or with alum, induced the greatest expansion of Env-specific
CD4+ T cells and this population was still present at week 15.
When the regimens were reversed, with NYVAC-CN54 as
prime and the protein-adjuvant combinations as boost, we
Figure 2. Robust antibody responses are induced by all vaccination regimens. Serum levels of total IgG (green triangles), IgG1 (black
circles) and IgG2a (red circles) were measured at weeks 5, 11 and 15. A) Mice were primed at weeks 0 and 3 with Env-CN54 gp140 with alum alone, or
a medium (‘‘med’’) or high concentration of IC31 with or without alum, and boosted at week 6 and 9 with NYVAC-CN54. B) Mice were primed at
weeks 0 and 3 with NYVAC-CN54 and boosted at week 6 and 9 with Env-CN54 gp140 protein in combination with the adjuvants as indicated. Total
IgG could not be detected in the control mice. The graphs show the antibody titers detected by ELISA at weeks 5, 11, and 15. Bars correspond to the
medians. *p,0.05.
doi:10.1371/journal.pone.0042163.g002
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observed a general trend for increased T-cell activation when the
adjuvant included IC31 (Fig. 3D). CD4+ T-cell responses were of
lower magnitude at week 11 as compared to protein prime/
NYVAC-CN54 boost. We could still detect a slightly superior
adjuvant activity with the high dose of IC31 plus alum, although
this response was only significantly different from alum alone and
the medium dose of IC31 plus alum (p,0.05 each; Fig. 3E). At
week 15, we detected a very low percentage of Env-specific CD4+
T cells secreting cytokines, and there were no significant
differences between groups (Fig. 3E).
Protein/IC31 adjuvant prime, NYVAC-CN54 boost
regimens induce superior Env-specific CD8+ T-cell
responses
We next evaluated the effect of the different regimens on the
activation status and cytokine production of CD8+ T cells. As a
marker of CD8+ T-cell activation we again utilized decreased
expression of CD62L. Two weeks after priming with protein/
adjuvant, there was a trend toward an increase in the percentage
of activated CD8+ T cells for all vaccine groups versus the saline
control (Fig. 4A). Two weeks after NYVAC-CN54 boost, we
detected a significant increase in CD8+ T-cell activation in all
vaccine groups versus the saline control (p,0.01 for alum only and
IC31 medium plus alum, p,0.05 for all others; Fig. 4A). At week
15, although the trend was the same, a significant difference versus
saline was observed only in the groups primed with protein and
alum alone or protein with the medium dose of IC31 alone
(p,0.05 each; Fig. 4A).
We next examined the effect of the different regimens on CD8+
T-cell cytokine production. We did not detect significant antigen-
specific CD8+ T-cell responses in any group following the protein/
adjuvant primes (Fig. 4B). After boosting, we detected cytokine
secretion in all groups, although there were significant differences
in frequencies between groups (Fig. 4B), with the greatest
difference observed between protein prime with the high dose of
IC31 plus alum versus protein prime with alum alone (2.74%
median frequency of response to peptide pool 1 versus 0.5%;
Fig. 4C). At week 15, we also observed a robust Env-specific
effector response in the CD8+ T-cell compartment in all groups
primed with protein and IC31, while the group primed with
protein and alum alone had a significantly lower response rate
(p,0.05 each; Fig. 4B). In summary, priming with protein and the
high dose of IC31 plus alum generated an Env-specific CD8+ T-
cell response with the highest magnitude and durability (Fig. 4C).
When the regimens were reversed, with NYVAC-CN54 prime
and the protein-adjuvant combinations as boost, CD8+ T-cell
activation followed a trend similar to that observed with the
protein prime/NYVAC-CN54 boost regimens (Fig. 4D). Follow-
ing protein boost, the groups for which IC31 was used as an
adjuvant showed an increase in CD8+ T-cell activation as
compared to alum alone or the saline control. At the memory
timepoint, we observed a trend toward increased CD8+ T-cell
activation in the groups boosted with protein and IC31 compared
to protein with alum alone or the saline control, although this only
reached significance for the high dose of IC31 alone versus the
saline control (p,0.05; Fig. 4D). While all adjuvant/protein
formulations elicited an elevated frequency of CD8+ T-cell
response over the saline control, none reached statistical signifi-
cance either directly after boosting or at the memory timepoint
(Fig. 4E).
IC31 promotes an enhanced memory response
Since priming with protein adjuvanted with IC31 induced
CD4+ and CD8+ T-cell responses that persisted, we further
investigated the ability of this regimen to induce immunological
memory. We first determined the number of memory precursors
two weeks after NYVAC-CN54 boost by measuring the number of
antigen-specific CD8+ T cells (producing TNF-a and/or IFN-c
following stimulation with peptide pool 1) that were
CD127+KLRG1- [22]. Mice primed with protein adjuvanted
with the high dose of IC31, with or without alum, had significantly
more memory precursors (p,0.05 each vs. alum only, Fig. 5A),
demonstrating that IC31 is superior to alum alone in terms of
inducing CD8+ T-cell memory precursors.
We next determined the number of central memory (TCM) and
effector memory (TEM) cells six weeks after boost by distinguishing
Env-specific CD8+ T cells by cytokine expression and further
gating on CD62L positive or negative cells, respectively [22]. The
greatest expansion of the central memory cell compartment
occurred when mice were primed with protein adjuvanted with
the high dose of IC31 plus alum (Fig. 5B). In all cases, adjuvanting
with IC31 resulted in significantly higher expansion than with
alum alone (p,0.05 each; Fig. 5B). Additionally, CD8+ T cells at
the memory timepoint had significantly increased proliferative
capacity when the high dose of IC31 was used, with or without
alum (p,0.01 each vs. alum only; Fig. 5C). This is consistent with
previous studies demonstrating that TCM cells are superior to TEM
cells in proliferation [23,24]. Finally, we found that a protein
prime including IC31, with or without alum, resulted in
significantly increased effector memory cell generation (p,0.05
each vs. alum only; Fig. 5D).
Env-specific CD8+ T cells are induced in the mesenteric
lymph nodes when the protein prime includes IC31
We next examined the Env-specific CD8+ T-cell response in the
mesenteric lymph nodes (MLN) following the protein prime/
NYVAC-CN54 boost vaccination regimens. Both immediately
following NYVAC-CN54 boost and at a memory timepoint there
were cytokine-secreting CD8+ T cells present in the MLN,
regardless of the adjuvant used. The percentages were similar at
the two timepoints and the pattern was comparable to that
observed in the spleens (Fig. 6A–B). Specifically, at week 11, the
high dose of IC31 plus alum induced the highest percentage of
Env-specific CD8+ T cells (0.094%, compared to 0.065% for IC31
Figure 3. Durable Env-CN54 specific CD4+ T-cell responses are detected following vaccinationwhen Env/alum/IC31 is used as a prime.
(A–C) Mice were primedwith Env-CN54 gp140 in combinationwith either alum alone or a medium (‘‘med’’) or high concentration of IC31 with or without
alum and then boosted with NYVAC-CN54 at three week intervals. A) Frequencies of activated CD4+ T cells as indicated by low CD62L expression at
weeks 5, 11 and 15. Each data point corresponds to a single mouse in the experimental group. B) Percentage of CD4 T cells secreting cytokines (TNF-a
and IFN-c) upon stimulation with four peptide pools covering the full length of Env-CN54 gp140, as determined by ICS. C) Kinetic analysis of the
frequencies of cytokine secreting CD4+ T cells following vaccination. Data points correspond to the medians of the frequencies obtained by stimulation
with peptide pool 1. D–E) Mice were primed with NYVAC-CN54 and boosted with Env-CN54 gp140 in combination with adjuvants as listed. (D)
Frequencies of activated CD4+ T cells as indicated by low CD62L expression at weeks 11 and 15. Each data point corresponds to a single mouse in the
experimental group. (E) Percentage of CD4+ T cells secreting cytokines at weeks 11 and 15. For B and E, data points following stimulation with peptide
pool 1 (red circles), pool 2 (green squares), pool 3 (green triangles) and pool 4 (black triangles) are distinguished, while the dotted line corresponds to the
average obtained upon DMSO stimulation. Bars correspond to median values (medians for peptide pool 1 stimulation only in B and E). *p,0.05.
doi:10.1371/journal.pone.0042163.g003
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high alone, 0.058% for IC31 medium alone, 0.036% for IC31
medium plus alum and 0.052% for alum alone). Six weeks after
boosting with NYVAC-CN54 we detected Env-specific TEM in the
MLN of mice that received the protein prime adjuvanted with the
high dose of IC31 plus alum. The number of TEM in these MLN
was significantly higher than in mice primed with protein and
alum alone, where Env-specific TEM were virtually undetectable
(p,0.05; Fig. 6C). We could not detect Env-specific CD4+ T cells
in the MLN of mice from any group (data not shown), despite
detecting a potent response in the spleen (Fig. 3).
Discussion
In our study, we tested the novel adjuvant IC31 in combination
with recombinant Env-CN54 protein in a heterologous prime-
boost vaccination regimen with a NYVAC-CN54 vector encoding
for the same Env variant. To our knowledge, this is the first study
Figure 4. Durable Env-CN54 gp140 specific CD8+ T-cell activation and cytokine secretion are detected following vaccination. (A–C)
Mice were primed with Env-CN54 gp140 in combination with alum alone, or with a medium (‘‘med’’) or high concentration of IC31 with or without
alum, and then boosted with NYVAC-CN54 at three week intervals. A) Frequencies of activated CD8+ T cells as indicated by low CD62L expression at
weeks 5, 11 and 15. Each data point corresponds to a single mouse in the experimental group. B) Percentage of CD8+ T cells secreting cytokines upon
stimulation with the four peptide pools, as determined by ICS. C) Kinetic analysis of the frequencies of cytokine secreting CD8+ T cells following
vaccination. Data points correspond to the medians of the frequencies obtained by peptide pool 1 stimulation. D–E) Mice were primed with NYVAC-
CN54 and boosted with Env-CN54 gp140 in combination with adjuvants as indicated. D) Frequencies of activated CD8+ T cells as indicated by low
CD62L expression at weeks 11 and 15. Each data point corresponds to a single mouse in the experimental group. E) Percentage of CD8+ T cells
secreting cytokines at weeks 11 and 15. Labels are as shown in Figure 3. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0042163.g004
Figure 5. The memory T-cell pool is enhanced by Env/IC31 prime. A) At week 11, the numbers of CD8+ memory precursor cells (IFN-c+ and/
or TNF-a+ CD8+ KLRG1-low CD127+) in the spleen were determined for mice that were primed with Env-CN54 gp140 with various adjuvants as
indicated and boosted with NYVAC-CN54. The graph shows the results obtained after in vitro stimulation with peptide pool 1. B) At week 15, memory
T-cell numbers were assessed in the spleen. Central memory T cells were defined as CD8+ T cells secreting IFN-c and/or TNF-a with high expression of
CD62L. The graph depicts central memory cell numbers induced by the various vaccination regimens following in vitro re-stimulation with peptide
pool 1. C) Proliferation of spleen CD8+ T cells from week 15 was determined by CFSE dilution. The graph shows the frequency of proliferating CD8+ T
cells following in vitro stimulation with peptide pool 1 for 3 days. D) Effector memory T cells from week 15 were defined as CD8+ T cells secreting IFN-
c and/or TNF-a, expressing low levels of CD62L. The graph shows the values obtained after in vitro stimulation with peptide pool 1. Bars indicate the
median value. *p,0.05 and **p,0.01. Each data point corresponds to a single mouse in the experimental group.
doi:10.1371/journal.pone.0042163.g005
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utilizing IC31 for an HIV vaccine immunogenicity study. IC31
was previously shown to induce Th1-like antibody immunity and
to facilitate isotype switching to IgG2a [25,26]. In the context of
HIV vaccines, this characteristic is particularly valuable, since the
importance of antibody functional activities other than neutrali-
zation, such as ADCC, has recently been highlighted by the
correlates analysis of the RV144 trial [27]. In our study, we
observed that adjuvanting a protein prime with IC31 induced
increased levels of IgG2a and lowered the ratio of IgG1/IgG2a as
compared to priming with protein plus alum alone. We also
showed that NYVAC-CN54 prime followed by protein boost
induced an elevated level of IgG2a antibodies, regardless of the
adjuvant used (Fig. 2), confirming that NYVAC-CN54 is an
excellent prime for antibody induction, as previously reported [9].
Isotype switching to IgG2a has been shown to be dependent on
production of IFN-c [28]. While CD4+ T-cell activation was
increased following protein prime at weeks 5 and 11 regardless of
the adjuvant used, inclusion of IC31 maintained this activation at
a later timepoint (Fig. 3A). Induction of a CD4+ T-cell response is
essential to prevent the exhaustion of CD8+ memory T cells upon
re-challenge [29]. This is particularly important when considering
the vaccination protocols often used for HIV vaccine trials, which
utilize multiple challenges with the same antigen, thus potentially
leading to exhaustion of CD8+ T cells in the absence of antigen-
specific CD4+ T cells. We hypothesize that the inclusion of IC31
prevented this exhaustion by maintaining CD4+ T-cell activation
(Fig. 4B). Importantly, the responses that we detected for both
CD4+ and CD8+ T cells were mostly induced by Env peptide pool
1, which includes sequences from the V1/V2 loops. Antibody
responses to the same region of similar Env proteins have been
recognized as one of the principal correlates of risk, associated with
a 43% reduction in infection in the RV144 trial vaccine recipients
[27].
Finally, the inclusion of IC31 in a protein prime induced a
higher number of Env-specific CD8+ T cells in the MLN (Fig. 6),
while we did not detect any antigen-specific CD4+ T-cell response
at this site. This is likely to be advantageous for an HIV vaccine,
since it will not increase the frequency of activated CD4+ T cells,
which are potential targets of the virus, at an important site of
replication. Moreover, the induction of CD8+ T-cell memory at a
mucosal site, and specifically in the gut, is likely to be important in
preventing HIV replication early after infection. This effect on
mucosal immunity might be one of the causes for the protection
from Chlamydia infection in a recent vaccination study where IC31
was used as the adjuvant [30].
Our results can likely be explained by the capacity of IC31 to
signal through TLR9/MyD88 and induce dendritic cell matura-
tion, which is thought to then be responsible for driving Th1
responses [30]. The different cellular distribution of TLR9 in mice
and humans has historically posed a problem with results gained
from mouse models not translating into humans [31]. Importantly,
however, IC31 has been administered in two clinical trials of
Figure 6. Detection of Env-CN54 gp140 specific CD8+ T cells in the GALT of vaccinated mice. The frequencies of CD8+ T cells secreting
cytokines in response to CN54 peptide pools were evaluated in the mesenteric lymph nodes (MLN) of vaccinated mice at week 11 (A) and at week 15
(B). Graphs show the median CD8+ T-cell responses from the MLN (white bars) and from spleen (black bars) following stimulation with peptide pool
1. C) Effector memory T-cell numbers within the MLN were determined as described for Figure 5. Each data point corresponds to a single mouse in
the experimental group.
doi:10.1371/journal.pone.0042163.g006
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tuberculosis vaccines in naı¨ve as well as in BCG-vaccinated and
TB-positive subjects, where it was shown to induce a Th1 immune
response with IFN-c secretion by PBMC [32]. Thus, we expect
IC31 to have a similar potent effect when included in an HIV
vaccine administered to humans.
Our study also demonstrates the advantages of combining two
distinct adjuvants, namely IC31 and alum, for inducing both T-
cell and antibody responses. IC31 has been shown to induce strong
type 1 immune response [21], while alum is known to induce type
2 immune responses [33].
In this vaccination schedule, the order of NYVAC-CN54 and
protein is important for the induction of a strong cellular response.
The efficacy of NYVAC-CN54 as a boost was reported in a recent
NHP study [34]. Our study likewise found that NYVAC-CN54
provided an excellent boost in terms of CD4+ and CD8+ T-cell
activation and function.
Conclusions
Our study reveals multiple innovative findings for the field of
HIV vaccinology. First, we showed that IC31 used in combination
with Env-CN54 in the priming phase of a vaccination regimen
induces isotype switching and the production of Env-specific
IgG2a. IC31 also increases the magnitude of CD4+ and CD8+
Env-specific T-cell responses, the development of a central
memory and effector memory compartment and the presence
and persistence of antigen-specific T cells in gut-associated
lymphoid tissues. Second, we demonstrated that priming with
NYVAC-CN54 followed by protein/adjuvant boost does not
induce B and T-cell immunity to the same extent as the reverse
vaccination strategy. Taken together, our study supports the use of
IC31 as a protein adjuvant for future HIV vaccine trials, in
combination with a viral vector boost, such as NYVAC-CN54.
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